Topic resource collection
Approved comparison material connected to this topic.
75 resourcesRead both sides
Here's the honest answer: the gap between what 2026 clinical research shows and what supplement vendors claim is enormous. Actual memory peptides require pharmaceutical-grade synthesis, precise amino acid sequencing, and cold-cha…
Melanotan II (MT-II) Broad-spectrum (MC1R/MC3R/MC4R) Daily subcutaneous Melanogenesis induction, legacy research protocols Unscheduled federally; restricted in CA/NY/IL for cosmetic use Effective but non-selective. Off-target eff…
BPC-157 VEGF upregulation, angiogenesis promotion, collagen synthesis acceleration Preclinical + case series (no RCTs in humans for spinal applications) 250–500mcg subcutaneously daily for 8–12 weeks Acute disc herniation, annula…
Kisspeptin-54 GnRH neuron activation → LH/FSH release 4–6.4 nmol/kg SC 90–120 min Maintained (no negative feedback suppression) Phase 2 trials (Imperial College, UK) MK-677 (Ibutamoren) Ghrelin receptor agonist → GH/IGF-1 elevati…
Melanotan I (Afamelanotide) Selective MC1R binding 0.5–1.0 mg subcutaneous injection daily for 10–14 days, then maintenance 2–3×/week FDA-approved for EPP only; off-label use unregulated Slower pigmentation onset (2–3 weeks), few…
BPC-157 VEGF upregulation, FAK-paxillin activation, angiogenesis <5% (cleaved by pepsin) Phase II trials, no FDA approval 200–500 μg daily subcutaneous Strongest preclinical data for ulcer repair; limited large-scale human trials…
The following table summarizes the peptide compounds under active investigation for female sexual health applications as of the 2026 research update: PT-141 (Bremelanotide) MC4R agonist. Dopamine modulation HSDD (hypoactive sexua…
Tyrosinase inhibitors and MC1R antagonists target different nodes in the melanogenesis pathway. And clinical outcomes differ accordingly. Tyrosinase inhibitors (tripeptides like GHK or oligopeptide-34) chelate copper ions in the …
Before selecting a peptide protocol, understanding the mechanistic differences determines realistic expectations and appropriate use cases. The table below compares the three peptides with the strongest 2024–2026 clinical backing…
Thymosin Alpha-1 (1.6mg 2×/week) T-cell regulation, Treg activation, cytokine suppression 67% met primary endpoint (≥30% symptom reduction) Subcutaneous injection $2,400–$3,200 (compounded) Phase 2 RCT, peer-reviewed Extended Dox…
MOTS-c Mitochondrial biogenesis signalling 18–22% increase in skeletal muscle ATP Moderate to strong (31% Chalder Fatigue Scale improvement) Phase 2 human trials (2026) Strongest evidence for peripheral energy enhancement. Requir…
BPC-157 Promotes angiogenesis via VEGF upregulation; accelerates soft tissue repair through fibroblast activation Phase 3 human trial (Nature Medicine Jan 2026): 42% faster healing vs placebo in 72-week study 98.8% (HPLC + third-…
The following table compares the three primary peptides used in joint health research as of 2026, based on updated clinical trial data and dosing protocols. BPC-157 VEGF pathway upregulation, angiogenesis in peri-cartilage tissue…
The peptide market expanded rapidly in 2025–2026, and with it came exaggerated claims. BPC-157 has human trial data for tendon healing and gastric ulcer repair. It does not have Phase 3 human data specifically for osteoarthritis …
P21 (CNTF derivative) CNTF receptor agonist → JAK-STAT signaling → BDNF gene upregulation High (~85% in rodent models) Transcriptional upregulation (2.3× baseline at 10 µg/kg) Preclinical only. No human ADHD trials Strongest mech…
BPC-157 VEGF upregulation, angiogenesis, nitric oxide pathway activation 250–500mcg daily subcutaneous, localized near injury site 28 days refrigerated in bacteriostatic water; <72 hours in sterile water Days 14–56 (proliferative…
Survodutide Dual GLP-1/GIP receptor agonist 18.3% (4.8mg weekly) 6.8 days Subcutaneous Phase 2 complete, Phase 3 enrolling Mazdutide Dual GLP-1/glucagon receptor agonist 17.1% (6mg weekly) 5.2 days Phase 3 complete, regulatory re…
BPC-157 VEGFR-2 upregulation, tight junction protein synthesis (occludin, claudin-1), angiogenesis Phase 2 RCT: 58% clinical response in Crohn's at 10mcg/kg SC daily (University of Zagreb, 2025) Subcutaneous injection No FDA-appr…
BPC-157 VEGFR2 activation, tight junction upregulation SC injection or oral (enteric) 250–500 mcg SC daily or 500–1000 mcg oral Increased occludin/ZO-1 by 34–47% in 72 hours Most versatile. Both mucosal healing and junction repai…
BPC-157 VEGF upregulation → angiogenesis Phase II diabetic ulcer trial: 42% faster healing vs standard care (University of Split, 2025) Topical or subcutaneous injection near injury site 5–7 days at 2–8°C once reconstituted Most …